Facts About Bravecto
BRAVECTO: THE FACTS ON ITS SAFETY PROFILE
To Help Answer Your Questions as a Pet Owner
Many of us at MSD Animal Health are veterinary surgeons and/ or pet owners and do what we do because of our love for animals. Their health and well-being is our top priority. We know that vets and pet owners look to us to provide accurate and balanced information about our products, which is why it is so important that we share the FACTS about Bravecto.
THE IMPORTANCE OF FLEA AND TICK PROTECTION
As you may be aware, fleas and ticks are not just a nuisance, but also pose animal and human health risks, as they can transmit disease (including Lyme disease, Babesiosis, Bartonellosis and others).
That’s why it’s critical to protect pets from these parasites and keep them out of homes. Bravecto is the only oral treatment that has been shown to quickly and effectively kill fleas and multiple tick species for 12 weeks in a single dose*. It also is effective for eight weeks against Rhipicephalus sanguineus ticks.
Over 125 million doses of Bravecto have been distributed in 85 countries. We are pleased with the overwhelmingly positive responses we’ve had from both vets and pet owners from throughout the world about the benefits of Bravecto.
EXTENSIVE SAFETY RESEARCH
- We are confident in the safety of Bravecto.
- Prior to its first approval by a regulatory agency, the safety profile of Bravecto was established through comprehensive clinical research studies.
- As part of the product approval process, regulatory agencies throughout the world have reviewed the Bravecto research data and have approved the product for sale in their countries, when used according to the product licence. Global safety surveillance of Bravecto use has provided additional compelling evidence of the safety profile of the product.
- In a well-controlled field study Bravecto was used concurrently with other medications, such as vaccines, anthelmintics, antibiotics and steroids. No adverse reactions were observed when Bravecto was used at the same time as other medications.1,2
- The overall worldwide reporting rate for adverse events for Bravecto remains classified as rare. The most common reported events are mild and transient gastrointestinal upset, which are consistent with, and noted on, the product licence.
- The evaluation of the safety of Bravecto that was established through 170 clinical research studies.
- Clinical research data and analysis of adverse events do not demonstrate a causal relationship between Bravecto and liver or kidney issues or cancer.
COMMITMENT TO ETHICS AND TRANSPARENCY
- As a responsible animal health company, we take every single report of a potential adverse event seriously.
- Whenever possible, we work with the pet owner and attending veterinary surgeon to assemble as much clinical information as we can to try to help determine the cause of a pet’s health issue, and whether or not the product may have been involved.
- It is important to critically examine the facts relating to adverse events vs. anecdotes that are not substantiated by science and medical evidence. A report does not mean causation.
- We report findings to governing regulatory agencies around the world (based on a country’s respective laws and policies), so that they can make a fully informed, scientific assessment about the safety of the product.
- We do this so that accurate safety and efficacy information is available for veterinary surgeons prescribing our products.
- We are Confident in the Safety of Bravecto.
Always consult with your own veterinary surgeon about the health and well-being of your pet, and when making a decision about flea and tick control products.
MSD Animal Health Companion Animal Technical Services and Pharmacovigilance Team 01908 685685
*Bravecto® has a 12-week duration of efficacy against flea and tick species indicated on the SPCs except Bravecto Chewable Tablets which also include an 8-week immediate and persistent killing activity against Rhipicephalus sanguineus. For further information refer to the relevant SPC.
1 Rohdich et al. Parasites & Vectors, 2014, 7: 83.
2 Walther et al. Plasma pharmacokinetic profile of fluralaner (Bravecto™) and ivermectin following concurrent administration to dogs. Parasites & Vectors (2015) 8:508. MSD